OncoSil Medical secures funding for cancer device launch

OncoSil Medical has secured commitments for A$5.6m ($4.03m) in new capital to launch its single-use brachytherapy device. Proceeds are earmarked for the commercial rollout of the OncoSil device in Australia and the US. OncoSil Medical expects a G-BA funded study, two European regulatory filings in the first half of FY27. Credit: Gorodenkoff / Shutterstock.com. Australian company OncoSil Medical, which develops targeted radiation therapies for difficult-to-treat cancers, has secured commitments for A$5.6m ($4.03m) in new capital to launch its single-use brachytherapy (internal radiation) device. These commitments were obtained from the company’s institutional shareholders, namely Australian Ethical Investments, Pengana High Conviction Equities…

Source: Medical Device Network